A review of therapeutic antibodies which have commercial potential. It discusses PCR cloning of Igs, immortalization by gene transfer, scale up production, infectious diseases, viruses, bacteria, parisites, inflammation/immunology, blood grouping, cells, cytokines, tumours and MDR.

Inhalt

The use of in vitro immunization, cloning of variable regions and scid mice for the production of human monoclonal antibodies; construction of recombinant therapeutic monoclonal antibodies; antibody-mediated cancer diagnosis and therapy; current status and future perspectives of chemoimmunoconjugates for the treatment of cancer; gangliosides as targets for monoclonal antibody therapy of cancer; mouse antibodies to carcinomas; therapeutic implication of monoclonal antibodies against multidrug resistant tumour cells; radioimmunotherapy with 90yttrium-anti-idiotype monoclonal antibody; immunoconjugates of a protein synthesis inhibiting drug; human monoclonal anti-idiotypic antibodies against a murine monoclonal antibody (Mab17-1A) as an anti-tumour vaccine; uses of human monoclonal antibodies to human cytomegalovirus and varicella-zoster virus; development of a human monoclonal antibody against cytomegalovirus with the aim of passive immunotherapy; characterization of human anti-cytomegalovirus monoclonal antibodies; immunoprotective capacities of human and murine monoclonal antibodies recognizing serotype specific and common determinants of gram-negative bacteria; pharmocokinetics of xomen TM-E5 in animals and humans; radomized placebo-controlled study of E5 monoclonal antiendotoxin antibody; human monoclonal antibodies against human red blood cells; CD7 monoclonal antibodies; large scale production of monoclonal antibodies; European regulatory issues.